Description:
Researchers at TGen and Northern Arizona University have developed a clinical rapid amplicon sequencing assay called Next-Gen Antibiotic Resistance Detection (N-GARD). N-GARD is a multiplexed, targeted sequence analysis system for the detection and characterization of antimicrobial resistance (AR) markers in critical Gram-negative bacteria typically associated with hospital acquired infections.
Multi-drug resistant hospital acquired infections are a grave threat to public health and clinical medicine. One of the last lines of defense is ensuring that treating clinicians have rapid and accurate antibiotic resistance data in order to make informed patient management decisions and to maintain judicious use of the limited therapeutic options. N-GARD targets many of the organisms that most commonly develop multi-drug resistance including Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli.
N-GARD enables pathogen detection and establishes an antimicrobial resistance genotype and phenotype profile directly from clinical samples. N-GARD is a highly-multiplexed, yet flexible, genotype and phenotype determination system that is capable of identifying all classes of AR mechanisms, including mutations, SNPs, mobile elements, gene amplification, and expression modulation, and can easily be modified to include additional pathogen targets and/or AR signatures.
Link to Issued US Patent 11,098,349
